Сравнение

Maridebart Cafraglutide vs. Pramlintid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Метаболизм

Номер CAS

нет данных

151126-32-8

Молекулярная масса

нет данных

3949.4 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Maridebart Cafraglutide

MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Maridebart Cafraglutide	Pramlintid
Германия	Не одобрено	Не одобрено
США	Не одобрено	Рецептурный

Полные записи

Maridebart Cafraglutide

Полная запись →

Pramlintid

Полная запись →

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Pramlintid?: Maridebart Cafraglutide is classified as "Метаболизм", while Pramlintid is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Maridebart Cafraglutide or Pramlintid?: The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Maridebart Cafraglutide and Pramlintid in Germany and the United States?: Германия: Maridebart Cafraglutide — Не одобрено, Pramlintid — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, Pramlintid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Maridebart Cafraglutide

Pramlintid

Германия

Не одобрено

США

Не одобрено

Рецептурный

Frequently asked questions

What is the difference between Maridebart Cafraglutide and Pramlintid?

Maridebart Cafraglutide is classified as "Метаболизм", while Pramlintid is classified as "Метаболизм". Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Maridebart Cafraglutide or Pramlintid?

The highest available evidence level is "РКИ на людях" for Maridebart Cafraglutide and "РКИ на людях" for Pramlintid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Maridebart Cafraglutide and Pramlintid in Germany and the United States?

Германия: Maridebart Cafraglutide — Не одобрено, Pramlintid — Не одобрено. США: Maridebart Cafraglutide — Не одобрено, Pramlintid — Рецептурный. These are factual summaries with source and review date on the individual pages.